Evidence map›Paper›PMID 41296198›Full record

ReviewMolecular neurobiology2025

Targeting O-GlcNAcylation: Novel Therapeutic Strategies for Neurological Disease.

Jingyi Sui, Lei Zheng, Baiwen Zhang, Yaxin Shang, Wei Zou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingyi SuiHeilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin, China.
Lei ZhengFirst Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin, China.
Baiwen ZhangFirst Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin, China.
Yaxin ShangHeilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin, China.
Wei ZouFirst Affiliated Hospital, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin, China. zouwei@hljucm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GlcNAcylation is a crucial post-translational modification. O-GlcNAcylation represents a dynamic monosaccharide modification that exhibits complex crosstalk with other post-translational modifications. It is ubiquitously present in nuclear, cytoplasmic, and mitochondrial proteins, participating in fundamental physiological processes such as cell adhesion and signal transduction. O-GlcNAcylation is particularly abundant in the brain, where it plays critical roles in nervous system development, synaptic plasticity, and energy metabolism. Functioning as both a nutrient sensor and signal integrator, O-GlcNAcylation holds significant importance in both the physiological and pathological processes of the nervous system. The development of pharmacological agents targeting O-GlcNAcylation has emerged as a major research focus. These agents have demonstrated therapeutic potential in animal models, including improving cognitive function, attenuating neuroinflammation, and inhibiting pathological protein aggregation. This review focuses on the roles of O-GlcNAc modification in neurological disorders and summarizes current drug development efforts targeting these conditions, aiming to provide novel perspectives for future research.

Indexed as

AcetylglucosamineMolecular Targeted TherapyNervous System DiseasesProtein Processing, Post-TranslationalAnimalsGlycosylationHumansAcetylglucosamineNeurodegenerationNeuropathyO-GlcNAcStroke

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.